1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nanobiotix
  6. Summary
    NANO   FR0011341205

NANOBIOTIX

(NANO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
05/11/2022 05/12/2022 05/13/2022 05/16/2022 05/17/2022 Date
5(c) 4.92(c) 5.05(c) 5.05(c) 5.3 Last
63 036 40 907 33 570 18 243 58 724 Volume
-1.38% -1.60% +2.64% 0.00% +4.95% Change
More quotes
Estimated financial data (e)
Sales 2022 1,25 M 1,32 M 1,32 M
Net income 2022 -52,1 M -54,9 M -54,9 M
Net Debt 2022 24,4 M 25,7 M 25,7 M
P/E ratio 2022 -3,37x
Yield 2022 -
Sales 2023 1,36 M 1,43 M 1,43 M
Net income 2023 -102 M -107 M -107 M
Net Debt 2023 2,66 M 2,80 M 2,80 M
P/E ratio 2023 -3,25x
Yield 2023 -
Capitalization 176 M 183 M 185 M
EV / Sales 2022 160x
EV / Sales 2023 131x
Nbr of Employees 100
Free-Float 94,5%
More Financials
Company
Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without increasing the... 
More about the company
Ratings of Nanobiotix
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about NANOBIOTIX
05/11NANOBIOTIX to Participate in Two Upcoming Investor Conferences
BU
05/04NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022
BU
05/02New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022..
BU
04/11Nanobiotix's Radiotherapy-activated Combination Therapy Shows Improved Anti-tumor Immun..
MT
04/11NANOBOTIX : New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation v..
PU
04/11NANOBOTIX : áNew Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation ..
BU
04/11Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the ..
CI
04/11NANOBIOTIX : Press Release, dated April 08, 2022 - Form 6-K
PU
04/11NANOBIOTIX : Report
CO
04/11NANOBIOTIX : SEC Filing 20 F
CO
04/08NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 An..
BU
04/08NANOBIOTIX : Form 20-f/a
PU
03/31NANOBIOTIX : Annual results
CO
03/30NANOBIOTIX : Inside Information / Other news releases
PU
03/30NANOBIOTIX : Provides Business Update and Reports Full Year 2021 Financial Results - Form ..
PU
More news
News in other languages on NANOBIOTIX
05/11Nanobiotix participera prochainement à deux conférences investisseurs
05/11Pic ou pas pic ?
05/11EN DIRECT DES MARCHES : Saint-Gobain, Alstom, Eiffage, Elis, Swedish Match, Twitter, Apple..
05/04Nanobiotix annoncera ses résultats financiers du premier trimestre 2022, le 18 mai 2022
05/03Les valeurs à suivre aujourd'hui à Paris - Mardi 3 mai 2022
More news
Analyst Recommendations on NANOBIOTIX
More recommendations
Chart NANOBIOTIX
Duration : Period :
Nanobiotix Technical Analysis Chart | NANO | FR0011341205 | MarketScreener
Technical analysis trends NANOBIOTIX
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 5,05 €
Average target price 22,90 €
Spread / Average Target 353%
EPS Revisions
Managers and Directors
Laurent LÚvy Chairman-Executive Board & Chief Executive Officer
Bart van Rhijn Chief Financial Officer
Gary M. Phillips Chairman-Supervisory Board
Margaret Galluzzi Vice President-Global & Head-Clinical Operations
Alain Dostie Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
NANOBIOTIX-30.92%183
MODERNA, INC.-46.35%54 199
LONZA GROUP AG-28.13%40 453
IQVIA HOLDINGS INC.-26.83%39 077
SEAGEN INC.-7.80%26 238
ICON PUBLIC LIMITED COMPANY-32.02%17 114